Información de la revista
Vol. 26. Núm. 6.
Páginas 381-395 (enero 2003)
Vol. 26. Núm. 6.
Páginas 381-395 (enero 2003)
Acceso a texto completo
Fibrogénesis y trasplante hepático
Visitas
5592
S. Benlloch, B. Beltrán, R. Moreno, M. Berenguer
Autor para correspondencia
mbhaym@teleline.es
Correspondencia: Dra. M. Berenguer. Servicio de Medicina Digestiva. Hospital Universitario La Fe. Avda. Campanar, 21. 46009 Valencia. España
Correspondencia: Dra. M. Berenguer. Servicio de Medicina Digestiva. Hospital Universitario La Fe. Avda. Campanar, 21. 46009 Valencia. España
Servicio de Medicina Digestiva. Hospital La Fe. Valencia. España
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S.L. Friedman.
Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury.
J Biol Chem, 275 (2000), pp. 2247-2250
[2.]
G. Ballardini, S. Degli Esposti, F.B. Bianchi, L.B. De Giorgi, A. Faccani, L. Biolchini, et al.
Correlation between Ito cells and fibrogenesis in an experimental model of hepatic fibrosis. A sequential stereological study.
Liver, 3 (1983), pp. 48-63
[3.]
F.J. Eng, S.L. Friedman, I. Fibrogenesis.
New insight into hepatic stellate cell activation: the simple becomes complex.
Am J Physiol, 279 (2000), pp. G7-G11
[4.]
J.J. Maher.
Leukocytes as modulators of stellate cell activation.
Alcohol Clin Exp Res, 23 (1999), pp. 917-921
[5.]
M. Pinzani, F. Marra.
Cytokine receptors and signaling in hepatic stellate cells.
Semin Liver Dis, 21 (2001), pp. 397-416
[6.]
D. Schuppan, M. Ruehl, R. Somasundaram, E.G. Hahn.
Matrix as a modulator of hepatic fibrogenesis.
Semin Liver Dis, 21 (2002), pp. 351-372
[7.]
F.J. Eng, S.L. Friedman.
Transcriptional regulation in hepatic stellate cells.
Semin Liver Dis, 21 (2001), pp. 385-395
[8.]
D.C. Rockey.
Hepatic blood flow regulation by stellate cells in normal and injured liver.
Semin Liver Dis, 21 (2001), pp. 337-349
[9.]
M. Pinzani, A. Gentilini, A. Caligiuri, R. De Franco, G. Pellegrini, S. Milani, et al.
Transforming growth factor b1 regulates platelet-derived growth factor subunit in human lier fat-storing cells.
Hepatology, 21 (1995), pp. 232-239
[10.]
M. Pinzani, S. Milani, C. Grappone, F.L. Weber, P. Gentilini, H.E. Abboud.
Expression of platelet derived growth factor and its receptors in a model of acute liver injury.
Hepatology, 19 (1994), pp. 701-707
[11.]
M. Pinzani, S. Milani, H. Herbst, R. De Franco, C. Grappone, A. Gentilini, et al.
Expression of platelet derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis.
Am J Pathol, 148 (1996), pp. 785-800
[12.]
C.J. Marshal.
Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.
Cell, 80 (1995), pp. 179-185
[13.]
F. Marra, A. Gentilini, M. Pinzani, G.G. Choudhury, M. Parola, H. Herbst, et al.
Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's actions on hepatic stellate cells.
Gastroenterology, 112 (1997), pp. 1297-1306
[14.]
G. Robino, M. Parola, F. Marra, A. Caligiuri, R.M. De Franco, E. Zamara, et al.
Interaction between 4-hydroxy-2,3-alkenals and the platelet-derived growth factor-beta receptor. Reduced tyrosine phosphorylatin and downstream signaling in hepatic stellate cells.
J Biol Chem, 275 (2000), pp. 40561-40567
[15.]
M. Pinzani, F. Marra, A. Caligiuri, R. De Franco, A. Gentilini, P. Failli, et al.
Inhibition by pentoxifylline of extracellular signal-regulated kinase activation by platelet-derived growth factor in hepatic stellate cells.
Br J Pharmacol, 119 (1996), pp. 1117-1124
[16.]
A. Mallat, C. Gallois, J. Tao, A. Habib, J. Machouf, P. Mavier, et al.
Platelet-derived growth factor-BB and thormbin generate positive and negative signals for human hepatic stellate cell proliferation. Role of a prostaglandin/cyclic AMP pathway and cross-talk with endothelin receptors.
J Biol Chem, 273 (1998), pp. 27300-27305
[17.]
S.R. Datta, A. Brunet.
Cellular survival: a play in three Akts.
Genes Dev, 13 (1999), pp. 2905-2927
[18.]
R. Mancini, A. Benedetti, A.M. Jezequel.
An interleukin-1 receptor antagonist decreases fibrosis induced by dimethylnitrosamine in rat liver.
Virchows Arch, 424 (1994), pp. 25-31
[19.]
V. Ankoma-Sey, Y. Wang, Z. Dai.
Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells.
Hepatology, 31 (2000), pp. 141-148
[20.]
A. Castilla, J. Prieto, N. Fausto.
Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy.
N Engl J Med, 324 (1991), pp. 933-940
[21.]
S.L. Friedman.
Cytokines and fibrogenesis.
Semin Liver Dis, 19 (1999), pp. 129-140
[22.]
D.M. Bissel, S.S. Wang, W.R. Jarnagin, F.J. Roll.
Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation.
J Clin Invest, 96 (1995), pp. 447-455
[23.]
D.S. Yoo, D.C. Rockey.
Endothelin receptor subtypes in liver injury: upregulation and differential signaling in myofibroblast contractility.
Hepatology, 32 (2000), pp. 328
[24.]
J. Massague.
How cells read TGF-beta signals.
Nat Rev Mol Cell Biol, 1 (2000), pp. 169-178
[25.]
M. Pinzani, S. Milani, R. De Franco, C. Grappone, A. Caligiuri, A. Gentilini, et al.
Endothelin-1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells.
Gastroenterology, 110 (1996), pp. 534-548
[26.]
J. Alam, N.M. Bass, P. Bacchetti, L. Gee, D.C. Rockey.
Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites.
Am J Gastroenterol, 95 (2000), pp. 199-203
[27.]
A. Mallat, F. Fouassier, A.M. Preaux, C.S. Gal, D. Raufaste, J. Rosenbaun, et al.
Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic Ito cells: an endothelin B receptor-mediated pathway.
J Clin Invest, 96 (1995), pp. 42-49
[28.]
R. Bataller, P. Ginés, J.M. Nicolás, M.N. Gorgib, E. García-Ramallo, V. Gasull, et al.
Angiotensin II induces contraction and proliferation of human hepatic stellate cells.
Gastroenterology, 118 (2000), pp. 1149-1156
[29.]
M. Pinzani, P. Failli, C. Ruocco, A. Casini, S. Milani, E. Baldi, et al.
Fat-storing cells as liver-specific pericytes: spatial dynamics of agonist-stimulated intracellular calcium transients.
J Clin Invest, 90 (1992), pp. 642-646
[30.]
F. Marra.
Hepatic stellate cells and the regulation of liver inflammation.
J Hepatol, 31 (1999), pp. 1120-1130
[31.]
E.C. Ledgerwood, J.S. Pober, J.R. Bradly.
Recent advances in the molecular basis of TNF signal transduction.
Lab Invest, 79 (1999), pp. 1041-1050
[32.]
T. Knittel, L. Muller, B. Saile, G. Ramadori.
Effect of tumour necrosis factor-alpha on proliferation, activation and protein synthesis of rat hepatic stellate cells.
J Hepatol, 27 (1997), pp. 1067-1080
[33.]
B. Saille, T. Knittel, N. Matthes, P. Schott, G. Ramadori.
CD95/CD95L-mediated apoptosis of the hepatic stellate cells. A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair.
Am J Pathol, 151 (1997), pp. 1265-1272
[34.]
N. Trim, S. Morgan, M. Evans, R. Issa, D. Fine, S. Afford, et al.
Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation.
Am J Pathol, 156 (2000), pp. 1235-1243
[36.]
M. Buck, D.J. Kim, K. Houglum, T. Hassanein, M. Chojkier.
c-myb modulates transcription of the alpha-smooth muscle actin gene in activated hepatic stellate cells.
Am J Physiol Gastrointest Liver Physiol, 278 (2000), pp. G321-G328
[37.]
P. Greenwel, J.A. Domínguez-Rosales, G. Mavi, A.M. Rivas-Estilla, M. Rojkind.
Hydrogen peroxide: a link between acetaldehyde-elicited alpha1(I) collagen gene upregulation and oxidative stress in mouse hepatic stellate cells.
Hepatology, 31 (2000), pp. 109-116
[38.]
M.J. Iraburu, J.A. Domínguez-Rosales, L. Fontana, A. Auster, E.R. García-Subijano, A. Covarrubias-Pinedo, et al.
Tumor necrosis factor alpha down-regulates expression of the alpha1(I) collagen gene in rat hepatic stellate cells through a p20C/EBPbeta-and C/EBPdelta-dependent mechanism.
Hepatology, 31 (2000), pp. 1086-1093
[39.]
A. Lang, R. Schonhoven, S. Tuvia, D.A. Brenner, R.A. Rippe.
Nuclear factor kappa B in proliferatrion, activation and apoptosis in rat hepatic stellate cells.
J Hepatol, 33 (2000), pp. 58
[40.]
D. Schuppan.
Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins.
Semin Liv Dis, 10 (1990), pp. 1-10
[41.]
B.H. Davis.
Transforming growth factor beta responsiveness is modulated by the extracellular collagen matrix during hepatic ito cell culture.
J Cell Physiol, 136 (1988), pp. 547-553
[42.]
M. Chiquet, M. Matthisson, M. Koch, M. Tannheimer, R. Chiquet-Ehrismannn.
Regulation of extracellular matrix synthesis by mechanical stress.
Biochem Cell Biol, 74 (1996), pp. 737-744
[43.]
D.C. Rockey, R.A. Weisiger.
Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance.
Hepatology, 24 (1996), pp. 240
[44.]
N. Kawada, T.A. Tran-Thi, H. Klein, K. Decker.
The contraction of hepatic stellate (Ito) cells stimulated with vasoactive abustances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus.
Eur J Biochem, 213 (1993), pp. 823
[45.]
M. Asbert, A. Gines, P. Gines.
Circulating levels of endothelin in cirrhosis.
Gastroenterology, 104 (1993), pp. 1485-1491
[46.]
S. Moncada, A. Higgs.
The L-arginine-nitric oxide pathway.
N Engl J Med, 329 (1993), pp. 2002-2012
[47.]
T.K. Gupta, M. Toruner, M.K. Chung, R.J. Groszmann.
Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats.
Hepatology, 28 (1998), pp. 926-931
[48.]
Q. Yu, R. Shao, H.S. Qian, S.E. George, D.C. Rockey.
Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension.
J Clin Invest, 105 (2000), pp. 741-748
[49.]
M. Prieto, M. Berenguer, A. Rimola, C. Losnaz, C. Barrios, G. Clemente, et al.
Liver Transplantation in hepatitis C: a Spanish multicenter experience.
Eur J Gastroenterol Hepatol, 10 (1998), pp. 771-776
[50.]
J.G. O'Grady, H.M. Smith, S.E. Davies, H.M. Daniels, P.T. Donaldson, K.C. Tan, et al.
Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications.
J Hepatol, 14 (1992), pp. 104-111
[51.]
O. Chazouilleres, D. Mamish, M. Kim, K. Casey, L. Ferrell, J.P. Roberts, et al.
«Occult» hepatitis B virus as source of infection in liver transplant recipients.
Lancet, 343 (1994), pp. 142
[52.]
T. Wright, E. Donegan, H. Hsu, L. Ferrell, J.R. Lake, M. Kim, et al.
Recurrent and acquired hepatitis C viral infection in liver transplant recipients.
Gastroenterology, 103 (1992), pp. 317-322
[53.]
M. Prieto, M. Berenguer, M. Rayon, J. Cordoba, L. Arguello, D. Carrasco, et al.
High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
Hepatology, 29 (1999), pp. 250-256
[54.]
M. Berenguer, L. Ferrell, J. Watson, M. Prieto, R. Kim, M. Rayon, et al.
HCV-related fibrosis progression following liver transplantation: increase in recent years.
J Hepatol, 32 (2000), pp. 673-684
[55.]
C. Feray, L. Caccamo, G.J.M. Alexander, G.S. Alexander, B. Ducot, V. Gugenheim, et al.
European Collaborative Study on factors influencing the outcome after liver transplantation for hepatitis C.
Gastroenterology, 117 (1999), pp. 619-625
[56.]
M. Charlton, E. Seaberg, R. Wiesner, J. Ferharst, R. Zetterman, J. Lake, et al.
Predictors of patient and graft survival following liver transplantation forhepatitis C.
Hepatology, 28 (1998), pp. 823-830
[57.]
M. Berenguer, M. Prieto, J.M. Rayon, J. Mora, M. Pastor, V. Ortiz, et al.
Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation.
Hepatology, 32 (2000), pp. 852-858
[58.]
M. Berenguer, M. Prieto, F. San Juan.
Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.
Hepatology, 36 (2002), pp. 202-210
[59.]
L.M. Forman, J.D. Lewis, J.A. Berlin, H.I. Feldman, M.R. Lucey.
The association between hepatitis C infection and survival after orthotopic liver transplantation.
Gastroenterology, 122 (2002), pp. 889-896
[60.]
M. Berenguer, M. Rayon, M. Prieto, V. Aguilera, D. Nicolas, V. Ortiz, et al.
Are post-transplantation protocol liver biopsies useful in the long-term?.
Liver transp, 7 (2001), pp. 790-796
[61.]
M. Guido, M. Rugge, G. Leandro, I. Fiel, S. Thung.
Hepatic stellate cel immunodetection and cirrhotic evolution of viral hepatitis in liver allografts.
Hepatology, 26 (1997), pp. 310-314
[62.]
K.W. Burak, W. Kremers, K. Batts, R.H. Wiesner, C.B. Rosen, R.R. Razonable, et al.
Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.
Liver Transpl, 8 (2002), pp. 362-369
[63.]
D. Samuel, R. Mueller, G. Alexander, L. Fassati, B. Ducot, S.P. Benhamou, et al.
Liver transplantation in European patients with the hepatitis B surface antigen.
N Engl J Med, 329 (1993), pp. 1842-1847
[64.]
Y.O. Kweon, Z.D. Goodman, J.L. Dienstag, E.R. Schiff, N.A. Brown, E. Burchardt, et al.
Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B.
J Hepatol, 35 (2001), pp. 749-755
[65.]
S.E. Davies, B.C. Portmann, J.G. O'Grady, P.M. Aldis, K. Chaggar, G.J. Alexander, et al.
Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis.
Hepatology, 13 (1991), pp. 150-157
[66.]
T.W. Faust.
Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation.
Liver Transpl, 7 (2001), pp. 99-108
[67.]
R. Bataller, D.A. Brenner.
Hepatic stellate cells as a target for the treatment of liver fibrosis.
Semin Liver Dis, 21 (2001), pp. 437-451
[68.]
J.F. Dufour, DeLellis, R, M.M. Kaplan.
Reversibility of hepatic fibrosis in autoinmune hepatitis.
Ann Intern Med, 127 (1997), pp. 981-985
[69.]
J.A. Solis, J.D. Morillas, M.T. Munoz.
Fibrogenesis hepatica.
Enfermedades digestivas. Tomo 3: Higado y vias biliares, pp. p1775-p1785
[70.]
D.W. Beno, R. Espinal, B.M. Edelstein, B.H. Davis.
Administration of prostaglandin E analogue reduces rat hepatic and Ito cell collagen gene expression and collagen accumulation after bile duct ligation injury.
Hepatology, 17 (1993), pp. 707-714
[71.]
A. Rambaldi, C. Gluud.
Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis.
Liver, 21 (2001), pp. 129-136
[72.]
H. Cortez-Pinto, P. Alexandrino, M.E. Camilo, A. Gouveia-Oliveira, P.M. Santos, M.M. Alves, et al.
Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial.
Eur J Gastroenterol Hepatol, 14 (2002), pp. 377-381
[73.]
M.G. Chiaramonte, A.W. Cheever, J.D. Malley, D.D. Donaldson, T.A. Wynn.
Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis.
Hepatology, 34 (2001), pp. 273-282
[74.]
S. Dharancy, V. Canva, L. Gambiez, J.C. Paris, P. Desreumaux.
Hepatic deficiency of interleukin 10 in chronic hepatitis C.
Gastroenterology, 119 (2000), pp. 1411
[75.]
D.R. Nelson, G.Y. Lauwers, J.Y. Lau, G.L. Davis.
Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders.
Gastroenterology, 118 (2000), pp. 655-660
[76.]
C. Gluud, E. Christensen.
Ursodeoxycholic acid for primary biliary cirrhosis.
Cochrane Database Syst Rev, (2002), pp. CD000551
[77.]
K. Houglum, A. Venkataramani, K. Lyche, M. Chojkier.
A pilot study of the effects of d-α-tocopherol on hepatic stellate cell activation in chronic hepatitis C.
Gastroenterology, 113 (1997), pp. 1069-1073
[78.]
A. Pares, R. Planas, M. Torres, J. Caballeria, J.M. Viver, D. Acero, et al.
Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial.
J Hepatol, 26 (1998), pp. 615-621
[79.]
H. Tsushima, S. Kawata, S. Tamura, N. Ito, Y. Shirai, S. Kiso, et al.
Reduced plasma transforming growth factor-β levels in patients with chronic hepatitis C after interferon-α therapy: association with regression of hepatic fibrosis.
J Hepatol, 30 (1999), pp. 1-7
[80.]
J. George, D. Roulot, V.E. Koteliansky, D.M. Bisell.
In vivo inhibition of rat stellate cell activation by soluble TGF beta type II receptor: a potential new therapy for hepatic fibrosis.
Proc Natl Acad Sci USA, 96 (1999), pp. 12719-12724
[81.]
Y. Yata, P. Gotwals, V. Koteliansky, D.C. Rockey.
Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-β soluble receptor: implications for antifibrotic therapy.
Hepatology, 35 (2002), pp. 1022-1030
[82.]
D.M. Bissell, D. Roulot, J. George.
Transforming growth factor β and the liver.
Hepatology, 34 (2001), pp. 859-867
[83.]
G.S. Baroni, L. D'Ambrosio, P. Curto, A. Casini, R. Manzini, A.M. Jezequel, et al.
Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis.
Hepatology, 23 (1996), pp. 1189-1199
[84.]
I. Sakaida, K. Uchida, Y. Matsumura, K. Okita.
Interferon gamma treatment prevents procollagen gene expression without affecting transforming growth factor-beta 1 expression in pig serum-induced rat liver fibrosis in vivo.
J Hepatol, 28 (1998), pp. 471-479
[85.]
H.L. Weng, W.M. Cai, R.H. Liu.
Animal experiment and clinical study of effect of gamma-interferon on hepatic fibrosis.
World J Gastroenterol, 7 (2001), pp. 42-48
[86.]
T. Poynard, J. McHutchison, G.L. Davis, R. Esteban-Mur, Z. Goodman, P. Bedossa, et al.
Impact of interferon alfa-2b and ribavirina on progression of liver fibrosis in patients with chronic hepatitis C.
Hepatology, 32 (2000), pp. 1131-1137
[87.]
R. Sobesky, P. Mathurin, F. Charlotte, J. Moussali, M. Olivi, M. Vidaud, et al.
Modelling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view.
Gastroenterology, 116 (1999), pp. 378-386
[88.]
A. Gallorini, M. Plebani, P. Pontisso, L. Chemello, M. Masiero, G. Mantovani, et al.
Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2a interferon.
Liver, 14 (1994), pp. 257-264
[89.]
K. Ishibashi, T. Kashiwagi, A. Ito, Y. Tanaka, M. Nagasawa, T. Toyama, et al.
Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C.
Hepatology, 24 (1996), pp. 27-31
[90.]
T. Suou, K. Hosho, Y. Kishimoto, Y. Horie, H. Kawasakia.
Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa.
Hepatology, 22 (1995), pp. 426-461
[91.]
L. Mazzoran, G. Tamaro, M.A. Mangiarotti, P. Marchi, S. Baracetti, U. Gerini, et al.
Effects of interferon therapy on fibrosis serum markers in HCV-positive chronic liver disease.
Eur J Gastroenterol Hepatol, 10 (1998), pp. 125-131
[92.]
A. Mitsuda, T. Suou, Y. Ikuta, H. Kawasaki.
Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C.
J Hepatol, 32 (2000), pp. 666-672
[93.]
F. Serejo, A. Costa, A. Gouveia, F. Ramalho, A. Batista, M. Carneiro de Moura.
α-interferon improves liver fibrosis in chronic hepatitis C. Clinical significance of the serum N-terminal propeptide of procollagen type III.
Dig Dis Sci, 46 (2001), pp. 1684-1689
[94.]
M. Bueno, A. Daneri, J. Armendariz-Borunda.
Colestasis-induced fibrosis is reduced by interferon α2a and is associated with elevated liver metalloprotease activity.
J Hepatol, 33 (2000), pp. 915-925
[95.]
B. Lavezzo, A. Franchello, A. Smedile, et al.
Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus twelve month course of interferon alfa 2b with ribavirin.
J Hepatol, 37 (2002), pp. 247-252
[96.]
A. Desmouliere, X. Guoxiong, A.M. Costa, I.M. Yousef, G. Gabbiani, B. Tuchweber.
Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells.
J Hepatol, 30 (1999), pp. 621-631
[97.]
C. Raetsch, J.D. Jia, G. Boigk, M. Bauer, E.G. Hahn, E.O. Riecken, et al.
Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis.
Gut, 50 (2002), pp. 241-247
[98.]
A. Mallat, A.M. Preaux, S. Blazejewski, D. Dhumeaux, J. Rosenbaum, P. Mavier.
Effect of simvastatin, an inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells.
Hepatology, 20 (1994), pp. 1589-1594
[99.]
J. Zhu, J. Wu, E. Frizell, S.L. Liu, R. Bashey, R. Rubin, et al.
Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis.
Gastroenterology, 117 (1999), pp. 1198-1204
[100.]
J. Davaille, C. Gallois, A. Habib, L. Li, A. Mallat, J. Tao, et al.
Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts.
J Biol Chem, 275 (2000), pp. 34628-34633
[101.]
I. Shimizu, Y. Mizobuchi, M. Yasuda, M. Shiba, Y.R. Ma, T. Horie, et al.
Inhibitory effect of oestradiol on activation of rat hepatic stellate cells in vivo and in vitro.
Gut, 44 (1999), pp. 127-136
[102.]
G. Paizis, R.E. Gilbert, M.E. Cooper, P. Murthi, J.M. Schembri, L.L. Wu, et al.
Effect of angiotensin II type I receptor blockade on experimental hepatic fibrosis.
J Hepatol, 35 (2001), pp. 376-385
[103.]
H. Yoshiji, S. Kuriyama, J. Yoshii, Y. Ikenaka, R. Noguchi, T. Nakatani, et al.
Angiotensin-II type I receptor interaction is a major regulator for liver fibrosis development in rats.
Hepatology, 34 (2001), pp. 745-750
[104.]
J. Vlachogiannakos, A.K. Tang, D. Patch, A.K. Burroughs.
Angiotensine converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.
Gut, 49 (2001), pp. 303-308
[105.]
J.J. Cho, B. Hocher, H. Herbst, J.D. Jia, M. Ruehl, E.G. Hahn, et al.
An oral endothelin A-receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis.
Gastroenterology, 118 (2000), pp. 1169-1178
[106.]
L. Dubuisson, A. Desmouliere, B. Decourt, L. Evade, C. Bedin, L. Boussarie, et al.
Inhibition of rat liver fibrogenesis through noradrenergic antagonism.
Hepatology, 35 (2002), pp. 325-331
[107.]
P. Failli, R.M. DeFranco, A. Caligiuri, A. Gentilini, R.G. Romanelli, F. Marra, et al.
Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells.
Gastroenterology, 179 (2000), pp. 479-492
[108.]
K. Okita, I. Sakaida, K. Hino.
Current strategies for chemoprevention of hepatocelular carcinoma.
Oncology, 62 (2002), pp. 24-28
[109.]
X.L. Zhang, L. Liu, H.Q. Jiang.
Salvia miltiorrhiza monomer IH 764-3 induces hepatic stellate cell apoptosis via caspase-3 activation.
World J Gastroenterol, 8 (2002), pp. 515-519
[110.]
P. Liu, Y. Hu, C. Liu, C. Liu, D. Zhu.
Effects of salviainolic acid A (SA-A) on liver injury: SA-A action on hepatic peroxidation.
Liver, 21 (2001), pp. 384-390
[111.]
S. Wasser, J.M. Ho, H.K. Ang, C.E. Tan.
Salvia miltiorrhiza reduces experimentally-induced hepatic fibrosis in rats.
J Hepatol, 29 (1998), pp. 760-771
[112.]
H. Kumada.
Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma.
Oncology, 62 (2002), pp. 94-100
[113.]
M. Watanabe, Y. Uchida, S. Sato, M. Moritani, S. Hamamoto, T. Mishiro, et al.
Report of a case showing a recovery from liver cirrhosis to chronic hepatitis, type C after glycyrrhizin injection for 2 years and a sustained response by the following interferon therapy.
Am J Gastroenterol, 96 (2001), pp. 1947-1949
[114.]
I. Sakaida, K. Uchida, K. Hironaka, K. Okita.
Prolyl 4-hydroxylase inhibitor (HOE 077) prevents TIMP-1 gene expression in rat liver fibrosis.
J Gastroenterol, 34 (1999), pp. 376-377
[115.]
M. Aoyagi, I. Sakaida, C. Suzuki, M. Segawa, Y. Fukumoto, K. Okita.
Prolyl 4-hydroxylase inhibitor is more effective for the inhibition of proliferation than for inhibition of collagen synthesis of rat hepatic stellate cells.
Hepatol Res, 23 (2002), pp. 1-6
[116.]
I. Sakaida, Y. Matsumura, M. Kubota, K. Kayano, K. Takenaka, K. Okita.
The prolyl 4-hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline-deficient Lamino acid-defined diet.
Hepatology, 23 (1996), pp. 755-763
[117.]
M. Pines, V. Knopov, O. Genina, I. Lavelin, A. Nagler.
Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis.
J Hepatol, 27 (1997), pp. 391-398
[118.]
R. Bruck, O. Genina, H. Aeed, R. Alexiev, A. Nagler, Y. Avni, et al.
Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats.
Hepatology, 33 (2001), pp. 379-386
[119.]
G. Spira, N. Mawasi, M. Paizi, N. Anbinder, O. Genina, R. Alexiev, et al.
Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats.
J Hepatol, 37 (2002), pp. 331-339
[120.]
A. Hagler, M. Pines.
Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis.
Transplantation, 68 (1999), pp. 1806-1809
[121.]
R. Hernandez-Munoz, M. Diaz-Munoz, J.A. Suarez-Cuenca, C. Trejo-Solis, V. Lopez, L. Sanchez-Sevilla, et al.
Adenosine reverses a preestablished CCl4 -induced micronodular cirrhosis through enhancing collagenolytic activity and stimulating hepatocyte cell proliferation in rats.
Hepatology, 34 (2001), pp. 677-687
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados